In previous studies, a series of corresponding biomarkers, including TMB, tumor neoantigen load (NAL), PD-L1 expression level, microsatellite instability (MSI), tumor microenvironment (TME) markers and T cell gene expression profiles (GEPs) (9, 10), have been found to predict the response of cancer to ICI therapy as well as patient prognosis. This evidence concerns the gene CD274 and neoplasm.